Ublituximab
Ublituximab is a chimeric monoclonal antibody targeting CD20 on B lymphocytes that depletes CD20-expressing B cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), with glycoengineering to enhance ADCC activity. It is approved for the treatment of relapsing forms of multiple sclerosis and has been investigated in B-cell malignancies including chronic lymphocytic leukemia and non-Hodgkin lymphoma. Its glycoengineered Fc region provides enhanced potency compared to non-engineered anti-CD20 antibodies.
Áreas Terapêuticas
Mecanismo de Ação
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
HBD / HBA
- / -
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Perguntas frequentes
Ublituximab is a chimeric monoclonal antibody targeting CD20 on B lymphocytes that depletes CD20-expressing B cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), with glycoengineering to enhance ADCC activity. It is approved for the treatment of relapsing forms of multiple sclerosis and has been investigated in B-cell malignancies including chronic lymphocytic leukemia and non-Hodgkin lymphoma. Its glycoengineered Fc region provides enhanced potency compared to non-engineered anti-CD20 antibodies.
As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.
Yes, Ublituximab is an approved drug. It has reached clinical phase 4. It is classified as a Antibody.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2108354. Open-access bioactivity database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="ublituximab"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/ublituximab/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/ublituximab/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/ublituximab/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="ublituximab"></drugfyi-drug>